COVID-19 mortality in cancer patients: a report from a tertiary cancer centre in India
Background
Cancer patients, especially those receiving cytotoxic therapy, are assumed to have a higher probability of death from COVID-19. We have conducted this study to identify the Case Fatality Rate (CFR) in cancer patients with COVID-19 and have explored the relationship of various clinical factors to mortality in our patient cohort.
Methods
All confirmed cancer cases presented to the hospital from June 8 to August 20, 2020, and developed symptoms/radiological features suspicious of COVID-19 were tested by Real-time polymerase chain reaction assay and/or cartridge-based nucleic acid amplification test from a combination of naso-oropharyngeal swab for SARS-CoV-2. Clinical data, treatment details, and outcomes were assessed from the medical records.
Results
Of the total 3,101 cancer patients admitted to the hospital, 1,088 patients were tested and 186 patients were positive for SARS-CoV-2. The CFR in the cohort was 27/186 (14.52%). Univariate analysis showed that the risk of death was significantly associated with the presence of any comorbidity (OR: 2.68; (95% CI [1.13–6.32]); P = 0.025), multiple comorbidities (OR: 3.01; (95% CI [1.02–9.07]); P = 0.047 for multiple vs. single), and the severity of COVID-19 presentation (OR: 27.48; (95% CI [5.34–141.49]); P < 0.001 for severe vs. not severe symptoms). Among all comorbidities, diabetes (OR: 3.31; (95% CI [1.35–8.09]); P = 0.009) and cardiovascular diseases (OR: 3.77; (95% CI [1.02–13.91]); P = 0.046) were significant risk factors for death. Anticancer treatments including chemotherapy, surgery, radiotherapy, targeted therapy, and immunotherapy administered within a month before the onset of COVID-19 symptoms had no significant effect on mortality.
Conclusion
To the best of our knowledge, this is the first study from India reporting the CFR, clinical associations, and risk factors for mortality in SARS-CoV-2 infected cancer patients. Our study shows that the frequency of COVID-19 in cancer patients is high. Recent anticancer therapies are not associated with mortality. Pre-existing comorbidities, especially diabetes, multiple comorbidities, and severe symptoms at presentation are significantly linked with COVID-19 related death in the cohort.
Top-30
Journals
|
1
2
|
|
|
Cancer Medicine
2 publications, 6.25%
|
|
|
South Asian Journal of Cancer
2 publications, 6.25%
|
|
|
Cureus
2 publications, 6.25%
|
|
|
Clinical Practice and Epidemiology in Mental Health
1 publication, 3.13%
|
|
|
Open Research Europe
1 publication, 3.13%
|
|
|
Aging
1 publication, 3.13%
|
|
|
Cancer Control
1 publication, 3.13%
|
|
|
Current Treatment Options in Oncology
1 publication, 3.13%
|
|
|
Nature Cancer
1 publication, 3.13%
|
|
|
Saudi Journal of Biological Sciences
1 publication, 3.13%
|
|
|
IJID Regions
1 publication, 3.13%
|
|
|
Critical Reviews in Oncology/Hematology
1 publication, 3.13%
|
|
|
Journal of Cancer Policy
1 publication, 3.13%
|
|
|
International Immunopharmacology
1 publication, 3.13%
|
|
|
Reviews in Medical Virology
1 publication, 3.13%
|
|
|
Indian Journal of Medical and Paediatric Oncology
1 publication, 3.13%
|
|
|
JAMA network open
1 publication, 3.13%
|
|
|
JCO Global Oncology
1 publication, 3.13%
|
|
|
Cancers
1 publication, 3.13%
|
|
|
Annals of Translational Medicine
1 publication, 3.13%
|
|
|
Cancer Research, Statistics, and Treatment
1 publication, 3.13%
|
|
|
Journal of Education and Health Promotion
1 publication, 3.13%
|
|
|
AIP Conference Proceedings
1 publication, 3.13%
|
|
|
Cell Communication and Signaling
1 publication, 3.13%
|
|
|
Journal of Medical Physics
1 publication, 3.13%
|
|
|
Journal of Ayurveda and Integrative Medicine
1 publication, 3.13%
|
|
|
International Journal of Cancer
1 publication, 3.13%
|
|
|
1
2
|
Publishers
|
1
2
3
4
5
|
|
|
Springer Nature
5 publications, 15.63%
|
|
|
Elsevier
5 publications, 15.63%
|
|
|
Wiley
4 publications, 12.5%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
3 publications, 9.38%
|
|
|
Georg Thieme Verlag KG
2 publications, 6.25%
|
|
|
Cold Spring Harbor Laboratory
2 publications, 6.25%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 3.13%
|
|
|
F1000 Research
1 publication, 3.13%
|
|
|
Impact Journals
1 publication, 3.13%
|
|
|
SAGE
1 publication, 3.13%
|
|
|
King Saud University
1 publication, 3.13%
|
|
|
American Medical Association (AMA)
1 publication, 3.13%
|
|
|
American Society of Clinical Oncology (ASCO)
1 publication, 3.13%
|
|
|
MDPI
1 publication, 3.13%
|
|
|
AME Publishing Company
1 publication, 3.13%
|
|
|
AIP Publishing
1 publication, 3.13%
|
|
|
1
2
3
4
5
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.